A5102799156- Inflammatory Bowel Disease
- Microscopic Colitis
- Immunodeficiency and Autoimmune Disorders
- Cytokine Signaling Pathways and Interactions
- Immune Cell Function and Interaction
- Helicobacter pylori-related gastroenterology studies
- T-cell and B-cell Immunology
- Chronic Lymphocytic Leukemia Research
- Celiac Disease Research and Management
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Gastric Cancer Management and Outcomes
- Systemic Lupus Erythematosus Research
- Electrohydrodynamics and Fluid Dynamics
- Viral gastroenteritis research and epidemiology
- Autoimmune and Inflammatory Disorders Research
- Immune Response and Inflammation
- Iron Metabolism and Disorders
- Clusterin in disease pathology
- Pregnancy and Medication Impact
- Drug Transport and Resistance Mechanisms
- Hepatitis C virus research
- Retinoids in leukemia and cellular processes
- Endometriosis Research and Treatment
- Ubiquitin and proteasome pathways
The Health Care Science Institute
2025
Institute of Science Tokyo
2025
The University of Tokyo
1994-2019
Kyoto Prefectural University of Medicine
2017-2019
Kitano Hospital
2008-2016
Hôpital Claude Huriez
2016
Showa University
2001-2013
Osaka University
1997-2011
University of Washington
2011
Virginia Mason Medical Center
2011
Abstract Proinflammatory cytokines have been demonstrated to play a crucial role in the pathogenesis of Crohn’s disease. Among those cytokines, strong expression IL-6 has repeatedly demonstrated. To examine for disease, we introduced anti-IL-6R mAb murine model colitis. Colitis was induced C.B-17-scid mice transferred with CD45RBhigh CD4+ T cells from BALB/c mice. Anti-IL-6R or rat IgG administered weekly after cell transfer. ICAM-1 and VCAM-1 were analyzed by immunohistochemistry. Colonic...
The cytokine IL-6 acts via a specific receptor complex that consists of the membrane-bound (mIL-6R) or soluble (sIL-6R) and glycoprotein 130 (gp130). In this study, we investigated role IL-6R components in asthma. We observed increased levels sIL-6R airways patients with allergic asthma as compared to those controls. addition, local blockade murine model late-phase after OVA sensitization by gp130–fraction constant led suppression Th2 cells lung. By contrast, mIL-6R induced expansion...
Abstract DCs play a key role in defense against infections and also preventing inflammatory autoimmune diseases. The response of to pathogens is tightly regulated by many mechanisms allow for appropriate, but not pathogenic, responses. We previously showed that with deficiencies two ITAM‐bearing signaling adapters, DAP12 FcRγ, produce more cytokines upon treatment Toll‐like receptor (TLR) agonists than WT DCs. Here, we investigated whether the TREM‐2 pairs inhibit TLR responses...
Infliximab (IFX) is one of the treatments choice for corticosteroid-refractory and corticosteroid-dependent ulcerative colitis (UC). A high serum trough level IFX (TL) reported to be associated with sustained efficacy during maintenance treatment. As part a phase 3 randomized controlled trial in UC, we assessed predictive value first TL at week 2 short- long-term response. Patients received intravenous 5 mg/kg or placebo weeks 0, 2, 6. evidence response by 8 continued treatment 14 22. was...
Background/AimsFatigue is a common symptom in patients with inflammatory bowel disease (IBD). The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale has demonstrated reliability and validity assessing fatigue IBD used worldwide. This study aimed to examine the current state among Japanese using FACIT-F compare these findings data from global studies through systematic review. MethodsData 488 treated at specialized clinic were analyzed. Patient characteristics, such as...
Mesalamine is the first-line drug for treatment of ulcerative colitis (UC). We directly compared efficacy and safety two mesalamine formulations induction remission in patients with UC.In a multicenter, double-blind, randomized study, 229 mild-to-moderate active UC were assigned to 4 groups: 66 65 received pH-dependent release formulation 2.4 g/day (pH-2.4 g) or 3.6 (pH-3.6 g), respectively; time-dependent 2.25 (Time-2.25 33 placebo (Placebo). The drugs administered three times daily eight...
Infliximab has shown beneficial effects in the treatment of Crohn's disease (CD). The aim this study was to assess 1) clinical efficacy shortening infusion interval from 8 4 weeks when patients had loss response during maintenance therapy, and 2) association between serum trough level efficacy.This an open-label prospective multicenter study. administered at 5 mg/kg with active CD 0, 2, 6. Week 10 responders received infliximab every thereafter. In those after week 14 switched weeks....
Background & AimsWe previously reported results from a prospective randomized controlled trial comparing the efficacy of adalimumab monotherapy versus combination with azathioprine for patients Crohn's disease (CD) who were naive to biologics and thiopurines. We performed subanalysis data this study evaluate factors associated endoscopic response mucosal healing in participants.MethodsWe compared simple scores CD between moderate severe active randomly assigned groups that received (n = 85)...
The current paradigm of major histocompatibility complex (MHC) and disease association suggests that efficient binding autoantigens by disease-associated MHC molecules leads to a T cell–mediated immune response resultant autoimmune sequelae. data presented below offer different model for this with diabetes. We used several mouse lines expressing levels I-Ag7 I-Ak on the nonobese diabetic (NOD) background evaluate role class II in previously described NOD cell autoproliferation. ratio...
Transfer of CD45RBhigh CD4+ T cells from normal mice to congenic SCID induces wasting disease, a murine model inflammatory bowel disease. In this model, colonic inflammation is considered be caused by disregulated Th1 response, and cytokines, especially IFN-gamma, have been suggested play an important role in the pathogenesis order elucidate potential IFN-gamma we transferred knockout (GKO) mice. The recipient were absolutely free symptoms clinical signs disease showed body-weight gain...
We aimed to clarify the efficacy, safety, and factors associated with remission on dose escalation in patients Crohn's disease showing loss of response (LOR) infliximab treatment 5 mg/kg at 8-week intervals a clinical trial.Thirty-nine LOR therapy started 10 per 8 weeks. was defined as both Disease Activity Index ≥175 weeks after infusion increase ≥50 from 4 infusion.At week first mg/kg, median (95% confidence interval) reduction 33 evaluated 95.0 (70.0-134.0), meeting primary endpoint....
Abstract Aim This study aimed to identify sexual satisfaction and related factors in Japanese patients with inflammatory bowel disease, as well the characteristics of who refrained from responding question. Methods A questionnaire survey was administered 499 patients, whom 492 were available for analysis. Sexual measured using 5‐point scale derived “I am satisfied my sex life” item Functional Assessment Chronic Illness Therapy‐Fatigue. Patient (sex, age, marital status, job status)...
Background: In recent years, various biomarkers of ulcerative colitis (UC) have emerged; however, few studies simultaneously examined the utility multiple for monitoring disease activity. Additionally, serum leucine-rich alpha-2 glycoprotein (LRG), a new biomarker, may show blunt response to anti-TNF antibody therapy. This prospective study explored effective that could monitor activity changes in patients with UC. addition, we effect therapy on LRG. Methods: Blood and stool samples were...
Oncostatin M (OSM) has been implicated in immune regulation, though its precise role remains elusive. Here we show that OSM plays a crucial the prevention of autoimmune diseases. OSM-deficient mice showed normal development T cells, B cells and DC; however, their thymus hypoplasia altered medullary structure. Autoantibodies against dsDNA accumulated glomerulonephritis developed aged mice. Apoptotic mice, administration dexamethasone young resulted massive accumulation apoptotic thymocytes...
The noninferiority of pH-dependent release mesalamine (Asacol) once daily (QD) to 3 times (TID) administration was investigated.This a phase 3, multicenter, randomized, double-blind, parallel-group, active-control study, with dynamic and stochastic allocation using central registration. Patients ulcerative colitis in remission (a bloody stool score 0, an disease activity index ≤2), received the study drug (Asacol 2.4 g/d) for 48 weeks. primary efficacy endpoint nonrecurrence rate assessed on...